Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics

Informations

• Publié par: frost-sullivan
• Nombre de lectures: 7
• Langue: English

Extrait

Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics

PR Newswire MOUNTAIN VIEW, California, Aug. 13, 2012

- The company's commitment and planning have made its flagship product an indispensable diagnostic tool for CUP patients MOUNTAIN VIEW, California,Aug. 13, 2012/PRNewswire/ -- Based on its recent analysis of the next-generation diagnostics market, Frost & Sullivan recognizes Rosetta Genomics with the 2012 North American Frost & Sullivan Award for Entrepreneurial Company of the Year. Rosetta Genomics successfully competes in a concentrated market and achieved significant product adoption, while bringing value to both patients and investors. A recent Frost & Sullivan analysis onthe United Statescancer biomarkers market confirmed the growing credibility of clinical microRNA biomarkers, as compared to other potential clinical biomarkers, such as circulating tumor cells. Rosetta Genomics was one of the first providers of microRNA-based diagnostics in 2007, and the platform is now clinically validated and featured in 37 peer- reviewed publications. Rosetta Genomics holds a leading patent position in the competitive microRNA diagnostics space. Building upon this foundation, it now has four microRNA-based diagnostic products on the market. The company's flagship product, the miRview® mets2, has become an indispensible tool for clinicians in the evaluation of their Cancer of Unknown/Uncertain Primary (CUP) patients. The miRview® mets2 assay measures the expression level of 64 microRNA biomarkers, which are then processed by an algorithm composed of two classifiers and a decision-maker that can accurately identify the origin of the patients' tumor for 42 different cancer tissue types, with 85 percent sensitivity and 99 percent specificity. Clinicians use Rosetta Genomics' assay to better diagnose CUP patients and get them on more optimal treatment plans. "Rosetta Genomics' perfectly executed strategic plan involved a highly differentiated flagship product, continuous clinical validation in peer-reviewed journals and post-marketing studies, and prioritization of crucial relationships," said Frost & Sullivan Research Analyst Winny Tan. "The true testament to the soundness of the company's growth strategy was obtaining critical Medicare coverage and current procedural terminology (CPT) code assignment for the miRview® mets2 test in June 2012." In addition to its razor-sharp focus on validating and commercializing miRview® mets2, Rosetta Genomics has been continuously pushing the envelope in R&D to create quality products. The company has tried to eliminate growth restraints and re-shifted focus to nourishing productive avenues. For instance, Rosetta Genomics terminated an exclusive product distribution rights agreement with another commercial laboratory inthe United Statesand opted to strengthen relationships with key contacts within the Medicare Administrative Contractor (MAC). The company's proactive pursuit and attainment of coverage from the local MAC, adjudicating claims for the assay,